Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Published:2019-12 Issue:10216 Volume:394 Page:2271-2281
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Poeschel Viola,Held Gerhard,Ziepert Marita,Witzens-Harig Mathias,Holte Harald,Thurner Lorenz,Borchmann Peter,Viardot Andreas,Soekler Martin,Keller Ulrich,Schmidt Christian,Truemper Lorenz,Mahlberg Rolf,Marks Reinhard,Hoeffkes Heinz-Gert,Metzner Bernd,Dierlamm Judith,Frickhofen Norbert,Haenel Mathias,Neubauer Andreas,Kneba Michael,Merli Francesco,Tucci Alessandra,de Nully Brown Peter,Federico Massimo,Lengfelder Eva,di Rocco Alice,Trappe Ralf,Rosenwald Andreas,Berdel Christian,Maisenhoelder Martin,Shpilberg Ofer,Amam Josif,Christofyllakis Konstantinos,Hartmann Frank,Murawski Niels,Stilgenbauer Stephan,Nickelsen Maike,Wulf Gerald,Glass Bertram,Schmitz Norbert,Altmann Bettina,Loeffler Markus,Pfreundschuh Michael

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

3. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60);Pfreundschuh;Lancet Oncol,2008

4. A predictive model for aggressive non-Hodgkin's lymphoma;N Engl J Med,1993

5. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era;Ziepert;J Clin Oncol,2010

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma;Cytokine;2024-10

2. 2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas;PET Clinics;2024-10

3. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs;Frontiers in Oncology;2024-09-11

4. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma;Annals of Hematology;2024-09-04

5. Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for diffuse large B-cell lymphoma: A systematic review and meta-analysis;Journal of the National Cancer Center;2024-09